Mabwell (688062.SH), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced that the Phase II clinical trial of its self-developed innovative anti-IL-11 ...
Knowable Magazine reports 2025 faced turmoil in U.S. science amid job cuts and budget slashes, yet saw advances in gene ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback